Fosbretabulin disodium
Based on 1 Customer Validation
Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 168555-66-6
- Formula: C18H19Na2O8P
- Molecular Weight:440.29
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
tubulin[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | GI50 |
0.32 μM
Compound: CA-4P; 3
|
Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 30580241] |
| A-375 | IC50 |
0.0016 μM
Compound: CA4P
|
Growth inhibition of human A375 cells measured after 48 hrs by MTS assay
Growth inhibition of human A375 cells measured after 48 hrs by MTS assay
|
[PMID: 27100701] |
| A498 | GI50 |
0.041 μg/mL
Compound: 1d
|
The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.
The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.
|
[PMID: 9572894] |
| A549 | IC50 |
0.0234 μM
Compound: CA4P
|
Growth inhibition of human A549 cells by MTS assay
Growth inhibition of human A549 cells by MTS assay
|
[PMID: 27100701] |
| A549 | IC50 |
0.4 μM
Compound: CA-4P
|
Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
|
[PMID: 30108925] |
| A549 | GI50 |
0.16 μM
Compound: CA-4P; 3
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30580241] |
| Bel-7402 | IC50 |
0.04 μM
Compound: CA-4p
|
Antiproliferative activity against human Bel-7402 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human Bel-7402 cells measured after 48 hrs by SRB assay
|
[PMID: 32113125] |
| BXPC-3 | GI50 |
0.23 μg/mL
Compound: 1b
|
Growth inhibition against human pancreas carcinoma cell line (BxPC-3)
Growth inhibition against human pancreas carcinoma cell line (BxPC-3)
|
[PMID: 15943482] |
| BXPC-3 | GI50 |
0.23 μg/mL
Compound: CA4P
|
Antitumor activity against human BxPC3 cells by sulforhodamine B assay
Antitumor activity against human BxPC3 cells by sulforhodamine B assay
|
[PMID: 19228038] |
| BXPC-3 | GI50 |
0.23 μg/mL
Compound: 1b, CA4P, Fosbretabulin
|
Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22324723] |
| Caov-3 cell line | IC50 |
13.11 nM
Compound: CA4P
|
Antiproliferative activity against human Caov3 cells measured after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human Caov3 cells measured after 96 hrs by Celltiter-Glo assay
|
[PMID: 27718473] |
| CCRF-CEM | IC50 |
95 nM
Compound: CA-4P, combretastatin A4P
|
Antiproliferative activity against human CEM cells after 96 hrs by Coulter counter method
Antiproliferative activity against human CEM cells after 96 hrs by Coulter counter method
|
[PMID: 25626146] |
| CCRF-CEM | IC50 |
0.011 μM
Compound: 4; CA-4P
|
Antiproliferative activity against human CEM cells after 96 hrs by coulter counting method
Antiproliferative activity against human CEM cells after 96 hrs by coulter counting method
|
[PMID: 29471122] |
| CCRF-CEM | IC50 |
0.011 μM
Compound: 7; CA-4P
|
Antiproliferative activity against human CEM cells measured after 96 hrs by Coulter counter method
Antiproliferative activity against human CEM cells measured after 96 hrs by Coulter counter method
|
[PMID: 30921759] |
| DU-145 | GI50 |
0.00072 μg/mL
Compound: 1b
|
Growth inhibition against human prostate cell line (DU-145)
Growth inhibition against human prostate cell line (DU-145)
|
[PMID: 15943482] |
| DU-145 | GI50 |
0.72 ng/mL
Compound: 1b
|
Growth inhibition against human prostate cell line (DU-145)
Growth inhibition against human prostate cell line (DU-145)
|
[PMID: 15943482] |
| DU-145 | GI50 |
0.0007 μg/mL
Compound: CA4P
|
Antitumor activity against human DU145 cells by sulforhodamine B assay
Antitumor activity against human DU145 cells by sulforhodamine B assay
|
[PMID: 19228038] |
| DU-145 | GI50 |
0.7 ng/mL
Compound: CA4P
|
Antitumor activity against human DU145 cells by sulforhodamine B assay
Antitumor activity against human DU145 cells by sulforhodamine B assay
|
[PMID: 19228038] |
| DU-145 | GI50 |
0.0072 μg/mL
Compound: 1b, CA4P, Fosbretabulin
|
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22324723] |
| DU-145 | GI50 |
0.016 μM
Compound: 3, CA4P
|
Cytotoxicity against human DU145 cells by SRB assay
Cytotoxicity against human DU145 cells by SRB assay
|
[PMID: 24016002] |
| DU-145 | GI50 |
0.00323 μM
Compound: CA4P
|
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
|
[PMID: 24183586] |
| DU-145 | IC50 |
0.0014 μM
Compound: CA4P
|
Growth inhibition of human DU145 cells measured after 48 hrs by MTS assay
Growth inhibition of human DU145 cells measured after 48 hrs by MTS assay
|
[PMID: 27100701] |
| DU-145 | GI50 |
0.00323 μM
Compound: CA-4P
|
Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 31059248] |
| FaDu | GI50 |
0.00045 μg/mL
Compound: 1b
|
Growth inhibition against human pharynx FADU cell line
Growth inhibition against human pharynx FADU cell line
|
[PMID: 15943482] |
| HCT-116 | IC50 |
0.0016 μM
Compound: CA4P
|
Growth inhibition of human HCT116 cells measured after 48 hrs by MTS assay
Growth inhibition of human HCT116 cells measured after 48 hrs by MTS assay
|
[PMID: 27100701] |
| HCT-116 | IC50 |
0.24 μM
Compound: CA-4P
|
Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
|
[PMID: 30108925] |
| HeLa | IC50 |
0.00043 μM
Compound: 2, CA4-P
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 19879758] |
| HeLa | IC50 |
0.43 nM
Compound: 2, CA4-P
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 19879758] |
| HeLa | IC50 |
79 nM
Compound: CA-4P, combretastatin A4P
|
Antiproliferative activity against human HeLa cells after 4 days by Coulter counter method
Antiproliferative activity against human HeLa cells after 4 days by Coulter counter method
|
[PMID: 25626146] |
| HeLa | IC50 |
0.013 μM
Compound: 4; CA-4P
|
Antiproliferative activity against human HeLa cells after 3 days by coulter counting method
Antiproliferative activity against human HeLa cells after 3 days by coulter counting method
|
[PMID: 29471122] |
| HeLa | IC50 |
0.56 μM
Compound: CA-4P
|
Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay
|
[PMID: 30108925] |
| HeLa | GI50 |
0.019 μM
Compound: CA-4P; 3
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30580241] |
| HeLa | IC50 |
0.013 μM
Compound: 7; CA-4P
|
Antiproliferative activity against human HeLa cells measured after 3 days by Coulter counter method
Antiproliferative activity against human HeLa cells measured after 3 days by Coulter counter method
|
[PMID: 30921759] |
| HepG2 | IC50 |
0.27 μM
Compound: CA-4P
|
Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 assay
|
[PMID: 30108925] |
| HepG2 | GI50 |
0.19 μM
Compound: CA-4P; 3
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 30580241] |
| HepG2 | IC50 |
0.002 μM
Compound: CA-4p
|
Antiproliferative activity against human HepG2 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human HepG2 cells measured after 48 hrs by SRB assay
|
[PMID: 32113125] |
| HMEC-1 | IC50 |
2.9 nM
Compound: CA-4P, combretastatin A4P
|
Antiproliferative activity against human HMEC1 cells after 4 days by Coulter counter method
Antiproliferative activity against human HMEC1 cells after 4 days by Coulter counter method
|
[PMID: 25626146] |
| HMEC-1 | IC50 |
0.0029 μM
Compound: 4; CA-4P
|
Antiproliferative activity against human HMEC1 cells after 4 days by coulter counting method
Antiproliferative activity against human HMEC1 cells after 4 days by coulter counting method
|
[PMID: 29471122] |
| HMEC-1 | IC50 |
0.0029 μM
Compound: 7; CA-4P
|
Antiproliferative activity against human HMEC1 cells measured after 4 days by Coulter counter method
Antiproliferative activity against human HMEC1 cells measured after 4 days by Coulter counter method
|
[PMID: 30921759] |
| HT-29 | IC50 |
0.2 μM
Compound: CA4P (disodium salt)
|
Cytotoxicity evaluated against colon cancer cell line (HT-29)
Cytotoxicity evaluated against colon cancer cell line (HT-29)
|
[PMID: 12699742] |
| HT-29 | GI50 |
0.062 μM
Compound: CA-4P; 3
|
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 30580241] |
| HUVEC | GI50 |
8 nM
Compound: CA4P
|
Growth inhibition of HUVEC after 72 hrs by crystal violet staining-based assay
Growth inhibition of HUVEC after 72 hrs by crystal violet staining-based assay
|
[PMID: 27690431] |
| Jurkat | EC50 |
15 nM
Compound: CA4P, Zybrestat
|
Cytotoxicity against human Jurkat cells assessed as cell viability after 48 hrs by trypan blue exclusion assay
Cytotoxicity against human Jurkat cells assessed as cell viability after 48 hrs by trypan blue exclusion assay
|
[PMID: 24387982] |
| K562 | IC50 |
0.72 μM
Compound: 7
|
Cytotoxicity against human K562 cells assessed as growth inhibition after 5 days by MTT assay
Cytotoxicity against human K562 cells assessed as growth inhibition after 5 days by MTT assay
|
[PMID: 28143677] |
| KB | IC50 |
0.66 nM
Compound: CA-4P
|
Antiproliferation activity against human KB cells measured after 72 hrs incubation by MTT assay
Antiproliferation activity against human KB cells measured after 72 hrs incubation by MTT assay
|
[PMID: 38781920] |
| KM-20L2 | GI50 |
0.53 μg/mL
Compound: 3c
|
Evaluated for growth inhibition (anticancer activity) of Human colon KM20L2 cancer cell line
Evaluated for growth inhibition (anticancer activity) of Human colon KM20L2 cancer cell line
|
[PMID: 10893310] |
| KM-20L2 | GI50 |
0.034 μg/mL
Compound: 1b, CA4P
|
Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 16252907] |
| KM-20L2 | GI50 |
0.034 μg/mL
Compound: 1b, CA4P, Fosbretabulin
|
Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22324723] |
| KM-20L2 | GI50 |
0.34 μg/mL
Compound: 1d
|
The compound was tested for the concentration to inhibit 50% of colon KM20L2 cell lines.
The compound was tested for the concentration to inhibit 50% of colon KM20L2 cell lines.
|
[PMID: 9572894] |
| L02 | IC50 |
140.18 nM
Compound: CA-4P
|
Antiproliferation activity against human L02 cells measured after 72 hrs incubation by MTT assay
Antiproliferation activity against human L02 cells measured after 72 hrs incubation by MTT assay
|
[PMID: 38781920] |
| L1210 | IC50 |
82 nM
Compound: CA-4P, combretastatin A4P
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by Coulter counter method
Antiproliferative activity against mouse L1210 cells after 48 hrs by Coulter counter method
|
[PMID: 25626146] |
| L1210 | IC50 |
0.0021 μM
Compound: 4; CA-4P
|
Antiproliferative activity against mouse L1210 cells after 96 hrs by coulter counting method
Antiproliferative activity against mouse L1210 cells after 96 hrs by coulter counting method
|
[PMID: 29471122] |
| L1210 | IC50 |
0.013 μM
Compound: 7; CA-4P
|
Antiproliferative activity against mouse L1210 cells measured after 96 hrs by Coulter counter method
Antiproliferative activity against mouse L1210 cells measured after 96 hrs by Coulter counter method
|
[PMID: 30921759] |
| MCF7 | IC50 |
0.002 μM
Compound: 2, CA4-P
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 19879758] |
| MCF7 | IC50 |
0.96 μM
Compound: CA-4P
|
Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay
|
[PMID: 30108925] |
| MCF7 | IC50 |
0.011 μM
Compound: CA-4p
|
Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells measured after 48 hrs by SRB assay
|
[PMID: 32113125] |
| MDA-MB-231 | IC50 |
0.0028 μM
Compound: CA4P
|
Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by MTS assay
Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by MTS assay
|
[PMID: 27100701] |
| MDA-MB-231 | IC50 |
173.3 nM
Compound: CA4P
|
Antiproliferative activity against human MDA-MB-231 cells measured after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human MDA-MB-231 cells measured after 96 hrs by Celltiter-Glo assay
|
[PMID: 27718473] |
| MDA-MB-231 | GI50 |
0.065 μM
Compound: CA-4P; 3
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 30580241] |
| MDA-MB-231 | IC50 |
3.66 nM
Compound: CA-4P
|
Antiproliferation activity against human MDA-MB-231 cells measured after 72 hrs incubation by MTT assay
Antiproliferation activity against human MDA-MB-231 cells measured after 72 hrs incubation by MTT assay
|
[PMID: 38781920] |
| MDA-MB-435 | IC50 |
8.75 nM
Compound: CA4P
|
Antiproliferative activity against human MDA-MB-435 cells measured after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human MDA-MB-435 cells measured after 96 hrs by Celltiter-Glo assay
|
[PMID: 27718473] |
| MGC-803 | IC50 |
0.47 μM
Compound: CA-4P
|
Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay
|
[PMID: 30108925] |
| MIA PaCa-2 | IC50 |
5.26 nM
Compound: CA-4P
|
Antiproliferation activity against human MIA PaCa-2 cells measured after 72 hrs incubation by MTT assay
Antiproliferation activity against human MIA PaCa-2 cells measured after 72 hrs incubation by MTT assay
|
[PMID: 38781920] |
| NCI-H460 | GI50 |
0.029 μg/mL
Compound: 3c
|
Evaluated for growth inhibition (anticancer activity) of Human CNS cancer SF-295 cell line
Evaluated for growth inhibition (anticancer activity) of Human CNS cancer SF-295 cell line
|
[PMID: 10893310] |
| NCI-H460 | GI50 |
0.00035 μg/mL
Compound: 1b
|
Growth inhibition against human lung-NSC NCI-H460 cell line
Growth inhibition against human lung-NSC NCI-H460 cell line
|
[PMID: 15943482] |
| NCI-H460 | GI50 |
0.35 ng/mL
Compound: 1b
|
Growth inhibition against human lung-NSC NCI-H460 cell line
Growth inhibition against human lung-NSC NCI-H460 cell line
|
[PMID: 15943482] |
| NCI-H460 | GI50 |
0.029 μg/mL
Compound: 1b, CA4P
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 16252907] |
| NCI-H460 | GI50 |
0.0004 μg/mL
Compound: CA4P
|
Antitumor activity against human NCI-H460 cells by sulforhodamine B assay
Antitumor activity against human NCI-H460 cells by sulforhodamine B assay
|
[PMID: 19228038] |
| NCI-H460 | GI50 |
0.4 ng/mL
Compound: CA4P
|
Antitumor activity against human NCI-H460 cells by sulforhodamine B assay
Antitumor activity against human NCI-H460 cells by sulforhodamine B assay
|
[PMID: 19228038] |
| NCI-H460 | GI50 |
0.029 μg/mL
Compound: 1b, CA4P, Fosbretabulin
|
Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22324723] |
| NCI-H460 | GI50 |
0.066 μM
Compound: 3, CA4P
|
Cytotoxicity against human NCI-H460 cells by SRB assay
Cytotoxicity against human NCI-H460 cells by SRB assay
|
[PMID: 24016002] |
| NCI-H460 | GI50 |
0.00194 μM
Compound: CA4P
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
|
[PMID: 24183586] |
| NCI-H460 | GI50 |
0.00194 μM
Compound: CA-4P
|
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 31059248] |
| NCI-H460 | IC50 |
0.29 nM
Compound: CA-4P
|
Antiproliferation activity against human NCI-H460 cells measured after 72 hrs incubation by MTT assay
Antiproliferation activity against human NCI-H460 cells measured after 72 hrs incubation by MTT assay
|
[PMID: 38781920] |
| NCI-H460 | GI50 |
0.029 μg/mL
Compound: 1d
|
The compound was tested for the concentration to inhibit 50% lung-NSC NCI-H460 cell lines.
The compound was tested for the concentration to inhibit 50% lung-NSC NCI-H460 cell lines.
|
[PMID: 9572894] |
| OVCAR | GI50 |
0.023 μg/mL
Compound: 1d
|
The compound was tested for the concentration to inhibit 50% of ovarian OVCAR cell lines.
The compound was tested for the concentration to inhibit 50% of ovarian OVCAR cell lines.
|
[PMID: 9572894] |
| P388 | GI50 |
0.0004 μg/mL
Compound: 3c
|
Evaluated for growth inhibition (anticancer activity) of Murine P388 lymphocytic leukemia cell line
Evaluated for growth inhibition (anticancer activity) of Murine P388 lymphocytic leukemia cell line
|
[PMID: 10893310] |
| P388 | GI50 |
0.4 ng/mL
Compound: 3c
|
Evaluated for growth inhibition (anticancer activity) of Murine P388 lymphocytic leukemia cell line
Evaluated for growth inhibition (anticancer activity) of Murine P388 lymphocytic leukemia cell line
|
[PMID: 10893310] |
| P388 | ED50 |
0.0004 μg/mL
Compound: 1c
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 10924176] |
| P388 | ED50 |
0.4 ng/mL
Compound: 1c
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 10924176] |
| P388 | ED50 |
0.0029 μg/mL
Compound: 1b
|
Effective dose against murine P388 leukemia cell line
Effective dose against murine P388 leukemia cell line
|
[PMID: 15943482] |
| P388 | ED50 |
0.0004 μg/mL
Compound: 1b, CA4P
|
Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 16252907] |
| P388 | ED50 |
0.4 ng/mL
Compound: 1b, CA4P
|
Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 16252907] |
| P388 | ED50 |
0.0004 μM
Compound: CA4P
|
Growth inhibition of mouse P388 cells
Growth inhibition of mouse P388 cells
|
[PMID: 18303849] |
| P388 | ED50 |
0.4 nM
Compound: CA4P
|
Growth inhibition of mouse P388 cells
Growth inhibition of mouse P388 cells
|
[PMID: 18303849] |
| P388 | ED50 |
0.0029 μg/mL
Compound: CA4P
|
In vivo antitumor activity against mouse P388 cells
In vivo antitumor activity against mouse P388 cells
|
[PMID: 19228038] |
| P388 | ED50 |
0.0004 μg/mL
Compound: 1b, CA4P, Fosbretabulin
|
Growth inhibition of mouse P388 cells after 48 hrs by Z1 Beckman/Coulter particle counter analysis
Growth inhibition of mouse P388 cells after 48 hrs by Z1 Beckman/Coulter particle counter analysis
|
[PMID: 22324723] |
| P388 | ED50 |
0.4 ng/mL
Compound: 1b, CA4P, Fosbretabulin
|
Growth inhibition of mouse P388 cells after 48 hrs by Z1 Beckman/Coulter particle counter analysis
Growth inhibition of mouse P388 cells after 48 hrs by Z1 Beckman/Coulter particle counter analysis
|
[PMID: 22324723] |
| P388 | GI50 |
0.0004 μg/mL
Compound: 1d
|
The compound was tested for the concentration to inhibit 50% of leukemia P388 cell lines.
The compound was tested for the concentration to inhibit 50% of leukemia P388 cell lines.
|
[PMID: 9572894] |
| P388 | GI50 |
0.4 ng/mL
Compound: 1d
|
The compound was tested for the concentration to inhibit 50% of leukemia P388 cell lines.
The compound was tested for the concentration to inhibit 50% of leukemia P388 cell lines.
|
[PMID: 9572894] |
| Panel NCI-60 (60 carcinoma cell lines) | GI50 |
1.28 μg/mL
Compound: 1d
|
The compound was tested for the concentration for 50% growth inhibition of NCI 60 cell line human tumor screen.
The compound was tested for the concentration for 50% growth inhibition of NCI 60 cell line human tumor screen.
|
[PMID: 9572894] |
| PBMC | IC50 |
0.17 μM
Compound: CA4P
|
Growth inhibition of human PBMC cells measured after 48 hrs by MTS assay
Growth inhibition of human PBMC cells measured after 48 hrs by MTS assay
|
[PMID: 27100701] |
| PC-3 | IC50 |
0.0062 μM
Compound: CA4P
|
Growth inhibition of human PC3 cells measured after 48 hrs by MTS assay
Growth inhibition of human PC3 cells measured after 48 hrs by MTS assay
|
[PMID: 27100701] |
| SF-268 | GI50 |
0.036 μg/mL
Compound: 1b, CA4P
|
Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 16252907] |
| SF-268 | GI50 |
0.036 μg/mL
Compound: 1b, CA4P, Fosbretabulin
|
Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22324723] |
| SF-295 | GI50 |
0.036 μg/mL
Compound: 3c
|
Evaluated for growth inhibition (anticancer activity) in Human CNS cancer SF-295 cell line
Evaluated for growth inhibition (anticancer activity) in Human CNS cancer SF-295 cell line
|
[PMID: 10893310] |
| SF-295 | GI50 |
0.036 μg/mL
Compound: 1d
|
The compound was tested for the concentration to inhibit 50% of CNS SF-295 cell lines.
The compound was tested for the concentration to inhibit 50% of CNS SF-295 cell lines.
|
[PMID: 9572894] |
| SK-MEL-5 | GI50 |
0.041 μg/mL
Compound: 1d
|
The compound was tested for the concentration to inhibit 50% of melanoma SK-MEL-5 cell lines.
The compound was tested for the concentration to inhibit 50% of melanoma SK-MEL-5 cell lines.
|
[PMID: 9572894] |
| SK-N-SH | GI50 |
0.00025 μg/mL
Compound: 1b
|
Growth inhibition against human neuroblastoma cell line (SK-N-SH)
Growth inhibition against human neuroblastoma cell line (SK-N-SH)
|
[PMID: 15943482] |
| SK-OV-3 | GI50 |
0.00119 μM
Compound: CA4P
|
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
|
[PMID: 24183586] |
| SK-OV-3 | IC50 |
0.0077 μM
Compound: CA4P
|
Growth inhibition of human SKOV3 cells measured after 48 hrs by MTS assay
Growth inhibition of human SKOV3 cells measured after 48 hrs by MTS assay
|
[PMID: 27100701] |
| SK-OV-3 | GI50 |
0.00119 μM
Compound: CA-4P
|
Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 31059248] |
| SW-1736 | GI50 |
0.00061 μg/mL
Compound: 1b
|
Growth inhibition against human thyroid cell line( SW 1736)
Growth inhibition against human thyroid cell line( SW 1736)
|
[PMID: 15943482] |
| TOV112D | IC50 |
30.85 nM
Compound: CA4P
|
Antiproliferative activity against human TOV112D cells measured after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human TOV112D cells measured after 96 hrs by Celltiter-Glo assay
|
[PMID: 27718473] |
Fosbretabulin disodium inhibits growth of leukemia P-388, pancreas BXPC-3,?neuroblast SK-N-SH, thyroid SW1736, lung-NSC NCI-H460, prostate DU-145, an pharynx FADU, with EC50s of 0.0029, 0.23, 0.00025, 0.00061, 0.00035, 0.00072, and 0.00045 μg/mL, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BD9 rats (7-9 weeks) bearing the s.c. implanted P22 tumor[3]
-
Dosage:100 mg/kg
-
Administration:A single i.p. injections
-
Result:Significantly raised the MABP by about 30%, and reduced the heart rate at 1 h after administration.
Reduced the blood flow in the tumor.
Chemical Information
-
CAS No. 168555-66-6
-
Appearance Solid
-
Molecular Weight 440.29
-
Formula C18H19Na2O8P
-
Color White to off-white
-
SMILES
COC1=C(OC)C(OC)=CC(/C=C\C2=CC=C(OC)C(OP(O[Na])(O[Na])=O)=C2)=C1
-
Synonyms
CA 4DP; CA 4P; Combretastatin A4 disodium phosphate
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : 4.5 mg/mL (10.22 mM; Need ultrasonic and warming)
DMF : < 1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 14.29 mg/mL (32.46 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shen CH, et, al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol. 2010 Aug;160(8):2008-27. [Content Brief]
[2]. Pettit GR, et, al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41. J Med Chem. 2005 Jun 16;48(12):4087-99. [Content Brief]
[3]. Tozer GM, et, al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999 Apr 1;59(7):1626-34. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.2712 mL | 11.3562 mL | 22.7123 mL | 56.7808 mL |
| 5 mM | 0.4542 mL | 2.2712 mL | 4.5425 mL | 11.3562 mL | |
| 10 mM | 0.2271 mL | 1.1356 mL | 2.2712 mL | 5.6781 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.